Genenta To Present Updated Phase I/II Data At Upcoming Scientific Congresses SNO AND ASH
16 Nov 2021
CollaborateGene Therapy
MILAN, Italy and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that it will be presenting updated preliminary Phase I/II clinical data on Temferon at two upcoming scientific congresses.
The Society for Neuro-Oncology (SNO) 2021 Annual Meeting and Education Day, November 18-21, Boston, USA
Title: TEM-GBM: A Phase I-IIa Dose-Escalation Study Delivering IFN-Α within Glioblastoma Multiforme Tumor Microenvironment by Genetically Modified TIE-2 Expressing Monocytes
Type: Poster presentation
Time: Friday November 19, 2021, 7.30 PM – 9.30 PM ET
63rd American Society of Hematology (ASH) Annual Meeting and Exposition 2021, December 11-14, Atlanta, USA and virtual
Title: TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN-α within Glioblastoma Tumor Microenvironment
Type: Poster presentation
Day: Sunday December 12, 2021, 6 PM – 8 PM ET
About Genenta Science
Genenta ( ) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Investor Relations - LifeSci Advisors
Genenta Media/Investor Contact
Mary-Ann Chang, CFA
Stefania Mazzoleni, PhD
+44 7483 28 48 53
+39 339 709 59 31
mchang@lifesciadvisors.com
stefania.mazzoleni@genenta.com
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.